Takeda Pharmaceutical Company Limited

Cardurion Pharmaceuticals, LLC

Exelixis, Inc.

X-ceptor Therapeutics, Inc.

Takeda California, Inc.

Haixia Wang

Mark Sabat

Nicholas Scorah

Phong H Vu

Christopher Ronald Smith

John David Lawson

Lily Kwok

Raju Mohan

Junya Shirai

Xiaolun Wang

Tomohiro Okawa

Keiko Kakegawa

Minoru Yoshida

John S Tyhonas

Terufumi Takagi

Yasufumi Miyamoto

Joanne Miura

Alan Thomas Johnson

Akito Shibuya

Rei Okamoto

Zenyu Shiokawa

Yuta Tanaka

Michael Charles Nyman

Yoichi Nishikawa

Edwin J Schweiger

Nobuyuki Matsunaga

Yoshito Terao

William C Stevens, Jr

Takafumi Yukawa

Mallareddy Komandla

Yinong Xie

Christopher D Bayne

Takeshi Yoshikawa

Takashi Nakahata

Hiroki Takahagi

Paul Tanis

Jeffrey Alan Stafford

Toufike Kanouni

Young K Chen

Stephen L Gwaltney

Zacharia S Cheruvallath

Anthony R Gangloff

Steven John Woodhead

Andrew John Jennings

Mingnam Tang

Walter Keung

Shao Po Lu

Shao-Po Lu

Christopher Smith

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.

Substituted amines for treating cardiac diseases

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.

Pyridinyl and fused pyridinyl triazolone derivatives

The present invention provides compounds of formula 1: which are useful as inhibitors of TBK-1, pharmaceutical compositionst thereof, methods for treatment of conditions associated with TBK1, processes for making the compounds and intermediates thereof.

Heteroarylamide inhibitors of TBK1

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R, R, R, R, and Rare defined in the specification. The compounds are inhibitors of Bruton's tyrosine kinase (BTK). This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with BTK.

Cinnoline derivatives

Compounds are provided for use with glucokinase that comprise the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Glucokinase activators

Compounds of the invention, such as compounds of formula (I): 

Modulators of LXR

Growing community of inventors

San Diego, CA, United States of America

Haixia Wang